For example, increased expression of ADORA2B, SLC7A1, ITGA5, RIPK2 and P2RX4 was associated with increased drug resistance of cancer cells to Ixazomib citrate, Homoharringtonine, Erlotinib, Tamoxifen, Elesclomol, LDK-378, Pipobroman, Decitabine, eribulin mesylate, ponatinib, carfilzomib, etc. On the contrary, increased expression of NOD2 and MEP1A was associated with increased drug sensitivity of cancer cells to a number of chemotherapy drugs such as Oxaliplatin, Nelfinavir, Entinostat, Tegafur, Benzimate and Paclitaxel. Here, MEP1A is linked to cancer.